Genetic background of idiopathic pulmonary fibrosis

Expert Review of Molecular Diagnostics

Volumn 13, Issue 4, 2013, Pages 389-406

  Santangelo, Simona ^a   Scarlata, Simone ^a   Zito, Anna ^a   Chiurco, Domenica ^a   Pedone, Claudio ^a   Incalzi, Raffaele Antonelli ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

DNA methylation; gene mutation; idiopathic pulmonary fibrosis; lung; microarray; miRNA; next generation sequencing

Indexed keywords

ABC TRANSPORTER; ABCA3 PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PHOSPHOLIPID; SURFACTANT PROTEIN C; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; ENVIRONMENTAL FACTOR; EXON; FIBROSING ALVEOLITIS; HIGH THROUGHPUT SCREENING; HISTOPATHOLOGY; HUMAN; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS PROTEINOSIS; LUNG LAVAGE; NONHUMAN; PHENOTYPE; PROGNOSIS; REVIEW; SENESCENCE;

DNA METHYLATION; GENETIC THERAPY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; MICRORNAS; MUTATION; PULMONARY SURFACTANT-ASSOCIATED PROTEIN C; RISK FACTORS;

EID: 84877304323     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/erm.13.22     Document Type: Review

References (116)

1. Raghu G, Collard HR, Egan JJ, et al.; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 183(6), 788-824 (2011).
2. Grutters JC, du Bois RM. Genetics of fibrosing lung diseases. Eur. Respir. J. 25(5), 915-927 (2005).
3. Castriotta RJ, Eldadah BA, Foster WM, et al. Workshop on idiopathic pulmonary fibrosis in older adults. Chest 138(3), 693-703 (2010).
4. Meltzer EB, Noble PW. Idiopathic pulmonary fibrosis. Orphanet J. Rare Dis. 3, 8 (2008).
5. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N. Engl. J. Med. 345(7), 517-525 (2001).
6. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 155(1), 242-248 (1997).
7. Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 347(8997), 284-289 (1996).
8. Jakab GJ. Sequential virus infection, bacterial superinfections and fibrogenesis. Am Rev Respir. Dis. 142, 374-379 (1990).
9. Pinsker KL, Schneyer B, Becker N, Kamholz SL. Usual interstitial pneumonia following Texas A2 influenza infection. Chest 80(2), 123-126 (1981).
10. Bremer LA, Blackman SM, Vanscoy LL, et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum. Mol. Genet. 17(14), 2228-2237 (2008).
11. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Sulc J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Tissue Antigens 67(3), 229-232 (2006).
12. García-Sancho C, Buendía-Roldán I, Fernández-Plata MR, et al. Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir. Med. 105(12), 1902-1907 (2011).
13. Weaver TE, Conkright JJ. Function of surfactant proteins B and C. Annu. Rev. Physiol. 63, 555-578 (2001).
14. Fisher JH, Emrie PA, Drabkin HA, et al. The gene encoding the hydrophobic surfactant protein SP-C is located on 8p and identifies an EcoRI RFLP. Am. J. Hum. Genet. 43(4), 436-441 (1988).
15. Glasser SW, Korfhagen TR, Perme CM, Pilot-Matias TJ, Kister SE, Whitsett JA. Two SP-C genes encoding human pulmonary surfactant proteolipid. J. Biol. Chem. 263(21), 10326-10331 (1988).
16. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 344(8), 573-579 (2001).
17. Thomas AQ, Lane K, Phillips J 3rd, et al. Heterozygosity for a surfactant protein C gene mutation associated with usual interstitial pneumonitis and cellular nonspecific interstitial pneumonitis in one kindred. Am. J. Respir. Crit. Care Med. 165(9), 1322-1328 (2002).
18. Brasch F, Griese M, Tredano M, et al. Interstitial lung disease in a baby with a de novo mutation in the SFTPC gene. Eur. Respir. J. 24(1), 30-39 (2004).
19. van Moorsel CH, van Oosterhout MF, Barlo NP, et al. Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort. Am. J. Respir. Crit. Care Med. 182(11), 1419-1425 (2010).
20. Lawson WE, Grant SW, Ambrosini V, et al. Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax 59(11), 977-980 (2004).
21. Markart P, Ruppert C, Wygrecka M, et al. Surfactant protein C mutations in sporadic forms of idiopathic interstitial pneumonias. Eur. Respir. J. 29(1), 134-137 (2007).
22. Selman M, Lin HM, Montaño M, et al. Surfactant protein A and B genetic variants predispose to idiopathic pulmonary fibrosis. Hum. Genet. 113(6), 542-550 (2003).
23. Wang Y, Kuan PJ, Xing C, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84(1), 52-59 (2009).
24. Shulenin S, Nogee LM, Annilo T, Wert SE, Whitsett JA, Dean M. ABCA3 gene mutations in newborns with fatal surfactant deficiency. N. Engl. J. Med. 350(13), 1296-1303 (2004).
25. Bullard JE, Wert SE, Whitsett JA, Dean M, Nogee LM. ABCA3 mutations associated with pediatric interstitial lung disease. Am. J. Respir. Crit. Care Med. 172(8), 1026-1031 (2005).
26. Young LR, Nogee LM, Barnett B, Panos RJ, Colby TV, Deutsch GH. Usual interstitial pneumonia in an adolescent with ABCA3 mutations. Chest 134(1), 192-195 (2008).
27. Armanios MY, Chen JJ, Cogan JD, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356(13), 1317-1326 (2007).
28. Tsakiri KD, Cronkhite JT, Kuan PJ, et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl Acad. Sci. USA 104(18), 7552-7557 (2007).
29. Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl Acad. Sci. USA 105(35), 13051-13056 (2008).
30. Mushiroda T, Wattanapokayakit S, Takahashi A, et al.; Pirfenidone Clinical Study Group. A genome-wide association study identifies an association of a common variant in TERT with susceptibility to idiopathic pulmonary fibrosis. J. Med. Genet. 45(10), 654-656 (2008).
31. Hodgson U, Pulkkinen V, Dixon M, et al. ELMOD2 is a candidate gene for familial idiopathic pulmonary fibrosis. Am. J. Hum. Genet. 79(1), 149-154 (2006).
32. Pulkkinen V, Bruce S, Rintahaka J, et al. ELMOD2, a candidate gene for idiopathic pulmonary fibrosis, regulates antiviral responses. FASEB J. 24(4), 1167-1177 (2010).
33. Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364(16), 1503-1512 (2011).
34. Zhang Y, Noth I, Garcia JG, Kaminski N. A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N. Engl. J. Med. 364(16), 1576-1577 (2011).
35. Hall FC, Bowness P. HLA and disease: From molecular function to disease association? In: HLA and MHC: Genes, Molecules, and Function. Browning MJ, McMichael AJ (Eds). BIOS Scientific Publishers Ltd, Oxford, UK, 353-381 (1996).
36. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat. Genet. 38(10), 1166-1172 (2006).
37. Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am. J. Respir. Crit. Care Med. 157(4 Pt 1), 1301-1315 (1998).
38. Stewart CA, Horton R, Allcock RJ, et al. Complete MHC haplotype sequencing for common disease gene mapping. Genome Res. 14(6, 1176-1187 (2004).
39. Falfán-Valencia R, Camarena A, Juárez A, et al. Major histocompatibility complex and alveolar epithelial apoptosis in idiopathic pulmonary fibrosis. Hum. Genet. 118(2), 235-244 (2005).
40. Aquino-Galvez A, Pérez-Rodríguez M, Camarena A, et al. MICA polymorphisms and decreased expression of the MICA receptor NKG2D contribute to idiopathic pulmonary fibrosis susceptibility. Hum. Genet. 125(5-6), 639-648 (2009).
41. Xue J, Gochuico BR, Alawad AS, et al. The HLA class II allele DRB1*1501 is over-represented in patients with idiopathic pulmonary fibrosis. PLoS ONE 6(2), e14715 (2011).
42. Desmoulière A, Geinoz A, Gabbiani F, Gabbiani G. Transforming growth factor-β induces β-smooth muscle actin expression in granulation tissue myofibroblasts and in quiescent and growing cultured fibroblasts. J. Cell Biol. 122(1), 103-111 (1993).
43. Bartram U, Speer CP. The role of transforming growth factor? In lung development and disease. Chest 125(2), 754-765 (2004).
44. Willis BC, Liebler JM, Luby-Phelps K, et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-γ1: potential role in idiopathic pulmonary fibrosis. Am. J. Pathol. 166(5), 1321-1332 (2005).
45. Khalil N, O'Connor RN, Unruh HW, et al. Increased production and immunohistochemical localization of transforming growth factor-γ in idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 5(2), 155-162 (1991).
46. Santana A, Saxena B, Noble NA, Gold LI, Marshall BC. Increased expression of transforming growth factor? isoforms (1, 2, 3) in bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 13(1), 34-44 (1995).
47. Xaubet A, Marin-Arguedas A, Lario S, et al. Transforming growth factor-γ1 gene polymorphisms are associated with disease progression in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 168(4), 431-435 (2003).
48. Li XX, Li N, Ban CJ, Zhu M, Xiao B, Dai HP. Idiopathic pulmonary fibrosis in relation to gene polymorphisms of transforming growth factor-ß1 and plasminogen activator inhibitor 1. Chin. Med. J. 124(13), 1923-1927 (2011).
49. Mattei MG, Mattei JF, Bernard R, Giraud F. Partial trisomy 4 resulting from a complex maternal rearrangement of chromosomes 2, 4, and 18 with interstitial translocation. Hum. Genet. 51(1), 55-61 (1979).
50. Sadoshima J, Izumo S. Molecular characterization of angiotensin 2-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of AT1 receptor subtype. Circ. Res. 97, 1952-1959 (1993).
51. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ. Res. 72(6), 1245-1254 (1993).
52. Villarreal FJ, Kim NN, Ungab GD, Printz MP, Dillmann WH. Identification of functional angiotensin II receptors on rat cardiac fibroblasts. Circulation 88(6), 2849-2861 (1993).
53. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 59(1), 31-38 (2004).
54. Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin- converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest 126(2), 438-446 (2004).
55. Cambien F, Alhenc-Gelas F, Herbeth B, et al. Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy Study. Am. J. Hum. Genet. 43(5), 774-780 (1988).
56. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 86(4), 1343-1346 (1990).
57. Fatini C, Gensini F, Sticchi E, et al. High prevalence of polymorphisms of angiotensin- converting enzyme (I/D) and endothelial nitric oxide synthase (Glu298Asp) in patients with systemic sclerosis. Am. J. Med. 112(7), 540-544 (2002).
58. Morrison CD, Papp AC, Hejmanowski AQ, Addis VM, Prior TW. Increased D allele frequency of the angiotensin-converting enzyme gene in pulmonary fibrosis. Hum. Pathol. 32(5), 521-528 (2001).
59. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 295(1), L178-L185 (2008).
60. Whyte M, Hubbard R, Meliconi R, et al. Increased risk of fibrosing alveolitis associated with interleukin-1 receptor antagonist and tumor necrosis factor-γ gene polymorphisms. Am. J. Respir. Crit. Care Med. 162(2 Pt 1), 755-758 (2000).
61. Hutyrová B, Pantelidis P, Drábek J, et al. Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 165(2), 148-151 (2002).
62. du Bois RM. The genetic predisposition to interstitial lung disease: functional relevance. Chest 121(Suppl. 3), 14S-20S (2002).
63. Pantelidis P, Fanning GC, Wells AU, Welsh KI, Du Bois RM. Analysis of tumor necrosis factor-γ, lymphotoxin-ω, tumor necrosis factor receptor II, and interleukin-polymorphisms in patients with idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 163(6), 1432-1436 (2001).
64. Whittington HA, Freeburn RW, Godinho SI, Egan J, Haider Y, Millar AB. Analysis of an IL-10 polymorphism in idiopathic pulmonary fibrosis. Genes Immun. 4(4), 258-264 (2003).
65. Vasakova M, Striz I, Slavcev A, Jandova S, Kolesar L, Scand J. Th1/Th2 cytokine gene polymorphisms in patients with idiopathic pulmonary fibrosis. Immunol. 65, 265-270 (2007).
66. Vasakova M, Striz I, Slavcev A, et al. Correlation of IL-1β and IL-4 gene polymorphisms and clinical parameters in idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 166, 346-351 (2011).
67. Barlo NP, van Moorsel CH, Korthagen NM, et al. Genetic variability in the IL1RN gene and the balance between interleukin (IL)-1 receptor agonist and IL-1ß in idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 166(3), 346-351 (2011).
68. Korthagen NM, van Moorsel CH, Kazemier KM, Ruven HJ, Grutters JC. IL1RN genetic variations and risk of IPF: a meta-analysis and mRNA expression study. Immunogenetics 64(5), 371-377 (2012).
69. Southcott AM, Jones KP, Li D, et al. Interleukin-8. Differential expression in lone fibrosing alveolitis and systemic sclerosis. Am. J. Respir. Crit. Care Med. 151(5), 1604-1612 (1995).
70. Keane MP, Belperio JA, Moore TA, et al. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol. 162(9), 5511-5518 (1999).
71. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte- derived neutrophil chemotactic factor IL-8. J. Immunol. 143(4), 1366-1371 (1989).
72. Hillian AD, Londono D, Dunn JM, et al.; CF Gene Modifier Study Group. Modulation of cystic fibrosis lung disease by variants in interleukin-8. Genes Immun. 9(6), 501-508 (2008).
73. Renzoni E, Lympany P, Sestini P, et al. Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis Rheum. 43(7), 1633-1640 (2000).
74. Ahn MH, Park BL, Lee SH, et al. A promoter SNP rs4073T>A in the common allele of the interleukin 8 gene is associated with the development of idiopathic pulmonary fibrosis via the IL-8 protein enhancing mode. Respir. Res. 12, 73 (2011).
75. Zorzetto M, Bombieri C, Ferrarotti I, et al. Complement receptor 1 gene polymorphisms in sarcoidosis. Am. J. Respir. Cell Mol. Biol. 27(1), 17-23 (2002).
76. Kubistova Z, Mrazek F, Lympany PA, et al. The CR1 C5507G polymorphism is not involved in susceptibility to idiopathic pulmonary fibrosis in two European populations. Tissue Antigens 72(5), 483-486 (2008).
77. Yuan YD, Zhao MX, Yu J. Association between genetic polymorphism of erythrocyte CR1 and the susceptibility of idiopathic pulmonary fibrosis. 34, 841-845 (2011).
78. Bournazos S, Woof JM, Hart SP, Dransfield I. Functional and clinical consequences of Fc receptor polymorphic and copy number variants. Clin. Exp. Immunol. 157(2), 244-254 (2009).
79. Bournazos S, Grinfeld J, Alexander KM, et al. Association of FcgRIIa R131H polymorphism with idiopathic pulmonary fibrosis severity and progression. BMC Pulm. Med. 10, 51 (2010).
80. Woessner JF Jr. The family of matrix metalloproteinase family. Ann. NY Acad. Sci. 732, 11-21 (1994).
81. Rutter JL, Mitchell TI, Butticè G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 58(23), 5321-5325 (1998).
82. Checa M, Ruiz V, Montaño M, Velázquez- Cruz R, Selman M, Pardo A. MMP-1 polymorphisms and the risk of idiopathic pulmonary fibrosis. Hum. Genet. 124(5), 465-472 (2008).
83. Zuo F, Kaminski N, Eugui E, et al. Gene expression analysis reveals matrilysin as a key regulator of pulmonary fibrosis in mice and humans. Proc. Natl Acad. Sci. USA 99(9), 6292-6297 (2002).
84. Kaminski N. Microarray analysis of idiopathic pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 29(Suppl. 3), S32-S36 (2003).
85. Selman M, Ruiz V, Cabrera S, et al. TIMP-1, -2, -3, and -4 in idiopathic pulmonary fibrosis. A prevailing nondegradative lung microenvironment? Am. J. Physiol. Lung Cell Mol. Physiol. 279(3), L562-L574 (2000).
86. Lemjabbar H, Gosset P, Lechapt-Zalcman E, et al. Overexpression of alveolar macrophage gelatinase B (MMP-9) in patients with idiopathic pulmonary fibrosis: effects of steroid and immunosuppressive treatment. Am. J. Respir. Cell Mol. Biol. 20(5), 903-913 (1999).
87. Swiderski RE, Dencoff JE, Floerchinger CS, Shapiro SD, Hunninghake GW. Differential expression of extracellular matrix remodeling genes in a murine model of bleomycininduced pulmonary fibrosis. Am. J. Pathol. 152(3), 821-828 (1998).
88. Ramos C, Montaño M, García-Alvarez J, et al. Fibroblasts from idiopathic pulmonary fibrosis and normal lungs differ in growth rate, apoptosis, and tissue inhibitor of metalloproteinases expression. Am. J. Respir. Cell Mol. Biol. 24(5), 591-598 (2001).
89. Wei LQ, Dong Y, Li ZH. [Effect of atorvastatin on MMP-9 and TIMP-1 levels in bronchoalveolar lavage fluid and serum of rats with bleomycin-induced pulmonary fibrosis]. Zhejiang Da Xue Xue Bao Yi Xue Ban 40(1), 64-70 (2011).
90. Ginsburg D, Zeheb R, Yang AY, et al. cDNA cloning of human plasminogen activatorinhibitor from endothelial cells. J. Clin. Invest. 78(6), 1673-1680 (1986).
91. Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. Haemophilia 14(6), 1255-1260 (2008).
92. Harold A. Disorders of lung matrix remodeling. J. Clin. Invest. 113, 148-157 (2004).
93. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb. Res. 99(2), 111-117 (2000).
94. Kotani I, Sato A, Hayakawa H, Urano T, Takada Y, Takada A. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb. Res. 77(6), 493-504 (1995).
95. Henry M, Tregouët DA, Alessi MC, et al. Metabolic determinants are much more important than genetic polymorphisms in determining the PAI-1 activity and antigen plasma concentrations: a family study with part of the Stanislas Cohort. Arterioscler. Thromb. Vasc. Biol. 18(1), 84-91 (1998).
96. Johanna GB, Michiel LB, Frits H, Cornelis K, Diederick EG. The 4G5G plymorphism in the gene for PAI-1 and the circadian oscillation of plasma PAI-1. Blood 101, 1841-1844 (2003).
97. Kim KK, Flaherty KR, Long Q, et al. A plasminogen activator inhibitor-1 promoter polymorphism and idiopathic interstitial pneumonia. Mol. Med. 9(1-2), 52-56 (2003).
98. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science 294(5543), 858-862 (2001).
99. Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br. J. Cancer 94(6), 776-780 (2006).
100. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2), 281-297 (2004).
101. Pandit KV, Corcoran D, Yousef H, et al. Inhibition and role of let-7d in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 182(2), 220-229 (2010).
102. Kass DJ, Kaminski N. Evolving genomic approaches to idiophatic pulmonary fibrosis: moving beyond genes. Clin. Transl. Sci. 4, 372-379 (2011).
103. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J. Exp. Med. 207(8), 1589-1597 (2010).
104. Cushing L, Kuang PP, Qian J, et al. miR-29 is a major regulator of genes associated with pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 45(2), 287-294 (2011).
105. Rabinovich EI, Kapetanaki MG, Steinfeld I, et al. Global methylation patterns in idiopathic pulmonary fibrosis. PLoS ONE 7(4), e33770 (2012).
106. Sanders YY, Ambalavanan N, Halloran B, et al. Altered DNA methylation profile in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 186(6), 525-535 (2012).
107. Lawson WE, Loyd JE, Degryse AL. Genetics in pulmonary fibrosis-familial cases provide clues to the pathogenesis of idiopathic pulmonary fibrosis. Am. J. Med. Sci. 341(6), 439-443 (2011).
108. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am. J. Respir. Crit. Care Med. 150(4), 967-972 (1994).
109. Ju W, Kim JW, Park NH, et al. Matrix metalloproteinase-1 promoter polymorphism and epithelial ovarian cancer: does ethnicity matter? J. Obstet. Gynaecol. Res. 33(2), 155-160 (2007).
110. Botto M, Theodoridis E, Thompson EM, et al. Fc gamma RIIa polymorphism in systemic lupus erythematosus (SLE): no association with disease. Clin. Exp. Immunol. 104(2), 264-268 (1996).
111. Chen JY, Wang CM, Wu JM, Ho HH, Luo SF. Association of rheumatoid factor production with FcgammaRIIIa polymorphism in Taiwanese rheumatoid arthritis. Clin. Exp. Immunol. 144(1), 10-16 (2006).
112. Vij R, Noth I. Peripheral blood biomarkers in idiopathic pulmonary fibrosis. Transl. Res. 159(4), 218-227 (2012).
113. Couch FJ, Weber BL. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. Breast Cancer Information Core. Hum. Mutat. 8(1), 8-18 (1996).
114. Dakhlallah D, Batte K, Wang Y, et al. Epigenetic regulation of miR-17∼92 contributes to the pathogenesis of pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 187(4), 397-405 (2013).
115. Hagaman JT, Kinder BW, Eckman MH. Thiopurine S- methyltransferase [corrected] testing in idiopathic pulmonary fibrosis: a pharmacogenetic cost-effectiveness analysis. Lung 188(2), 125-132 (2010).
116. Center DM, Schwartz DA, Solway J, et al. Genomic medicine and lung diseases. Am. J. Respir. Crit. Care Med. 186(3), 280-285 (2012).